Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Kyowa Kirin stops development of skin condition treatment
3 Reasons Growth Investors Will Love Kirin (KNBWY)
Kirin (KNBWY) Upgraded to Buy: What Does It Mean for the Stock?
Is Kirin (KNBWY) Stock Undervalued Right Now?
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Should Value Investors Buy Kirin (KNBWY) Stock?
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Is Kirin (KNBWY) Stock Outpacing Its Consumer Staples Peers This Year?
Are Investors Undervaluing Kirin (KNBWY) Right Now?
Kirin (KNBWY) Expected to Announce Earnings on Thursday
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Should Value Investors Buy Kirin (KNBWY) Stock?
Kirin (OTCMKTS:KNBWY) vs. Crimson Wine Group (OTCMKTS:CWGL) Head to Head Contrast
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
Is Kirin (KNBWY) Outperforming Other Consumer Staples Stocks This Year?
Should Value Investors Buy Kirin (KNBWY) Stock?
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
Kirin Holdings: Q1 Performance Had Mixed Takeaways
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
KNBWY vs. BUD: Which Stock Is the Better Value Option?
Are Investors Undervaluing Kirin (KNBWY) Right Now?
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
KNBWY or BUD: Which Is the Better Value Stock Right Now?
Is Kirin (KNBWY) Stock Undervalued Right Now?
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
Kirin Holdings: Improving The Sustainability Of Black Tea Farms In Sri Lanka Through The Regenerative Tea Scorecard In Conjunction With The Rainforest Alliance
Kirin Holdings: Conducting Human Rights Due Diligence For Sustainable Sourcing Of Sri Lankan Tea Leaves
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
KNBWY vs. DEO: Which Stock Is the Better Value Option?
Should Value Investors Buy Kirin (KNBWY) Stock?
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies